<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01636414</url>
  </required_header>
  <id_info>
    <org_study_id>051114B</org_study_id>
    <nct_id>NCT01636414</nct_id>
    <nct_alias>NCT01514474</nct_alias>
  </id_info>
  <brief_title>Reinfusion Drains vs Tranexamic Acid in Total Joint Arthroplasty</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>OrthoCarolina Research Institute, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>OrthoCarolina Research Institute, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is widely reported that a large percentage of total joint replacement patients receive
      allogeneic (human donor blood) blood transfusions due to perioperative blood loss with
      numbers ranging from 30% to 80%.

      The risks of allogenic blood transfusion are well documented in the literature. In addition,
      they are time-consuming: often lengthening hospital stay and decreasing the availability for
      postoperative physical therapy. Moreover, they are costly at several hundred dollars per
      unit, and allogeneic transfusions are linked with immunosuppression and increased
      postoperative infection rates and wound healing problems, which are devastating complications
      in this elective, joint replacement population. Several options are available for diminishing
      the need for allogenic blood transfusion following elective total joint replacement. These
      include the use of perioperative blood salvage devices (OrthoPAT) and tranexamic acid. While
      there is data to support the use of both OrthoPat and Tranexamic acid in primary total joint
      arthroplasty, there is little information comparing one versus the other in terms of efficacy
      and economics.

      The purpose of this study is to compare the safety, effectiveness and cost benefit of Hemovac
      drain, OrthoPAT and Tranexamic Acid to manage blood loss during total hip and total knee
      replacement surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood Transfusion</measure>
    <time_frame>Inpatient Postoperative, on average 3 days after surgery</time_frame>
    <description>Transfusion Rate (i.e, number of participants needing Blood Transfusion) Between Treatment Groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Hemoglobin Level</measure>
    <time_frame>Post-operative on day 2 (first day after surgery)</time_frame>
    <description>Change in hemoglobin following surgery. Initial (baseline) measure was prior to surgery on day of surgery. Follow-up measurement occurred the day following surgery.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">204</enrollment>
  <condition>Total Joint Arthroplasty</condition>
  <arm_group>
    <arm_group_label>Hemovac drain</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Re-infusion drain</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tranexamic drain</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hemovac drain</intervention_name>
    <description>The Hemovac drain is a device placed under your skin used to collect blood during surgery.</description>
    <arm_group_label>Hemovac drain</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Re-infusion drain</intervention_name>
    <description>This device is used during and after surgery to collect blood lost during this time and prepares the blood for possible reinfusion.</description>
    <arm_group_label>Re-infusion drain</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Tranexamic drain</intervention_name>
    <description>Tranexamic Acid is a synthetic amino acid that prevents the breakdown of blood clots which reduces bleeding.</description>
    <arm_group_label>Tranexamic drain</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients presenting for primary unilateral hip or knee arthroplasty

          2. &gt; 18 years of age

          3. Preoperative hemoglobin on day of surgery &gt; 10mg/dL

        Exclusion Criteria:

          1. Patients with a preoperative Hgb &lt; 10mg/dL

          2. Patients who are unwilling to consent to blood transfusions

          3. Patients with a history of bleeding disorder

          4. Patients on anticoagulation therapy preoperatively (ASA 325mg, Plavix or Coumadin)

          5. Patients with a history of Thromboembolic events ( DVT, PE, CVA MI)

          6. Patients with platelet counts &lt; 100,000

          7. Patients with kidney disease (Serum Cr &gt; 1.2)

          8. Patients with end stage renal disease or on hemodialysis

          9. Patients with renal transplant

         10. Patients presenting for bilateral total hip or knee arthroplasty

         11. Patients presenting for conversion or revision total hip or knee procedures

         12. Patients donating pre-autologous blood

         13. Patients with primary hematologic disease or malignancy

         14. Patients with allergy to Tranexamic Acid

         15. Patients with hepatic disease

         16. Patients not discontinuing steroid use prior to surgery

         17. Patients with religious beliefs/practices prohibiting blood transfusions

         18. Patients with cognitive impairment

         19. Patients who are terminally ill
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>OrthoCarolina, PA</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2012</study_first_submitted>
  <study_first_submitted_qc>July 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2012</study_first_posted>
  <results_first_submitted>March 23, 2016</results_first_submitted>
  <results_first_submitted_qc>March 23, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 25, 2016</results_first_posted>
  <last_update_submitted>July 21, 2016</last_update_submitted>
  <last_update_submitted_qc>July 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Total joint arthroplasty, blood loss</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Hemovac Drain</title>
          <description>Hemovac drain: The Hemovac drain is a device placed under your skin used to collect blood during surgery.</description>
        </group>
        <group group_id="P2">
          <title>Re-infusion Drain</title>
          <description>Re-infusion drain: This device is used during and after surgery to collect blood lost during this time and prepares the blood for possible reinfusion.</description>
        </group>
        <group group_id="P3">
          <title>Tranexamic Drain</title>
          <description>Tranexamic drain: Tranexamic Acid is a synthetic amino acid that prevents the breakdown of blood clots which reduces bleeding.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="66"/>
                <participants group_id="P3" count="74"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="60"/>
                <participants group_id="P3" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All patients who completed the study are included in the reported results. Patients that were withdrawn from the study did not receive treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Hemovac Drain</title>
          <description>Hemovac drain: The Hemovac drain is a device placed under your skin used to collect blood during surgery.</description>
        </group>
        <group group_id="B2">
          <title>Re-infusion Drain</title>
          <description>Re-infusion drain: This device is used during and after surgery to collect blood lost during this time and prepares the blood for possible reinfusion.</description>
        </group>
        <group group_id="B3">
          <title>Tranexamic Drain</title>
          <description>Tranexamic drain: Tranexamic Acid is a synthetic amino acid that prevents the breakdown of blood clots which reduces bleeding.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="61"/>
            <count group_id="B2" value="60"/>
            <count group_id="B3" value="65"/>
            <count group_id="B4" value="186"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.03" spread="8.21"/>
                    <measurement group_id="B2" value="63.77" spread="7.87"/>
                    <measurement group_id="B3" value="61.07" spread="14.31"/>
                    <measurement group_id="B4" value="62.68" spread="10.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Blood Transfusion</title>
        <description>Transfusion Rate (i.e, number of participants needing Blood Transfusion) Between Treatment Groups</description>
        <time_frame>Inpatient Postoperative, on average 3 days after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hemovac Drain</title>
            <description>Hemovac drain: The Hemovac drain is a device placed under your skin used to collect blood during surgery.</description>
          </group>
          <group group_id="O2">
            <title>Re-infusion Drain</title>
            <description>Re-infusion drain: This device is used during and after surgery to collect blood lost during this time and prepares the blood for possible reinfusion.</description>
          </group>
          <group group_id="O3">
            <title>Tranexamic Drain</title>
            <description>Tranexamic drain: Tranexamic Acid is a synthetic amino acid that prevents the breakdown of blood clots which reduces bleeding.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Transfusion</title>
          <description>Transfusion Rate (i.e, number of participants needing Blood Transfusion) Between Treatment Groups</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Hemoglobin Level</title>
        <description>Change in hemoglobin following surgery. Initial (baseline) measure was prior to surgery on day of surgery. Follow-up measurement occurred the day following surgery.</description>
        <time_frame>Post-operative on day 2 (first day after surgery)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hemovac Drain</title>
            <description>Hemovac drain: The Hemovac drain is a device placed under your skin used to collect blood during surgery.</description>
          </group>
          <group group_id="O2">
            <title>Re-infusion Drain</title>
            <description>Re-infusion drain: This device is used during and after surgery to collect blood lost during this time and prepares the blood for possible reinfusion.</description>
          </group>
          <group group_id="O3">
            <title>Tranexamic Drain</title>
            <description>Tranexamic drain: Tranexamic Acid is a synthetic amino acid that prevents the breakdown of blood clots which reduces bleeding.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hemoglobin Level</title>
          <description>Change in hemoglobin following surgery. Initial (baseline) measure was prior to surgery on day of surgery. Follow-up measurement occurred the day following surgery.</description>
          <units>g/dl</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.95" lower_limit="-5.0" upper_limit="-3.1"/>
                    <measurement group_id="O2" value="-3.80" lower_limit="-4.7" upper_limit="-3.1"/>
                    <measurement group_id="O3" value="-2.90" lower_limit="-3.80" upper_limit="-2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Hemovac Drain</title>
          <description>Hemovac drain: The Hemovac drain is a device placed under your skin used to collect blood during surgery.</description>
        </group>
        <group group_id="E2">
          <title>Re-infusion Drain</title>
          <description>Re-infusion drain: This device is used during and after surgery to collect blood lost during this time and prepares the blood for possible reinfusion.</description>
        </group>
        <group group_id="E3">
          <title>Tranexamic Drain</title>
          <description>Tranexamic drain: Tranexamic Acid is a synthetic amino acid that prevents the breakdown of blood clots which reduces bleeding.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Occluded superficial femoral artery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Reoperation</sub_title>
                <description>Reoperation during index hospitalization stay</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Extended hospitalization</sub_title>
                <description>Extended hospitalization stay, beyond the standard of care of 3 post-operative days.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Research Scientist</name_or_title>
      <organization>OrthoCarolina Research Institute</organization>
      <phone>704-323-2265</phone>
      <email>susan.odum@orthocarolina.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

